Can Neuropsychiatric Side Effects Develop After Years of Montelukast Use?
Yes, nightmares and insomnia can develop even after years of continuous montelukast therapy without prior side effects, and if these symptoms emerge, you should discontinue the medication immediately.
Understanding the Risk Profile
The FDA label explicitly states that neuropsychiatric events have been reported "mostly during SINGULAIR treatment" but critically notes that timing of onset is variable and unpredictable 1. The label does not specify that these events only occur early in treatment—in fact, the postmarketing surveillance data demonstrates that these adverse effects can emerge at any point during therapy, regardless of prior tolerance 1.
Key Evidence on Late-Onset Neuropsychiatric Effects
Drug-induced nightmares and insomnia are well-documented adverse effects that include dream abnormalities, insomnia, and sleep disturbances as part of the broader neuropsychiatric spectrum associated with montelukast 1.
The mechanism involves CNS penetration: Animal studies demonstrate that montelukast distributes into brain tissue, though the exact mechanisms underlying neuropsychiatric events remain incompletely understood 1.
Recent large-scale observational data confirms sleep disorder associations: A 2022 propensity-matched cohort study of 154,946 patients found increased odds of insomnia (OR 1.15,95% CI 1.05-1.27) in allergic rhinitis patients exposed to montelukast 2. A 2025 cross-sectional analysis of 16,520 adults from NHANES 2005-2018 demonstrated that montelukast exposure was associated with sleep disorders (OR 1.72,95% CI 1.32-2.26) 3.
Nightmares are particularly prominent: A 2022 analysis of 1,118 reports in VigiBase found that about half of nightmare reports were classified as serious, with two-thirds occurring in children, and many describing severe impact on daily life 4. Importantly, this study noted that "in most cases, the nightmares disappeared upon discontinuation of the drug but for some patients it took a long time until the nightmares ceased" 4.
Clinical Action Algorithm
If Nightmares or Insomnia Develop:
Immediately discontinue montelukast as advised by FDA labeling: "If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue SINGULAIR and contact a healthcare provider immediately" 1.
Provide supportive monitoring because symptoms may persist after discontinuation—the FDA label explicitly warns: "In many cases, symptoms resolved after stopping SINGULAIR therapy; however, in some cases symptoms persisted after discontinuation of SINGULAIR. Therefore, continue to monitor and provide supportive care until symptoms resolve" 1.
Do not restart montelukast: The FDA instructs to "re-evaluate the benefits and risks of restarting treatment with SINGULAIR if such events occur" 1—given the availability of alternative therapies for both asthma and allergic rhinitis, restarting is rarely justified.
Important Caveats
No predictable timeline exists: The FDA label acknowledges that "it is difficult to identify risk factors for or quantify the risk of NP events with SINGULAIR use" 1. This means prior tolerance does not predict future tolerance.
The risk applies to all age groups: Neuropsychiatric events "have been reported in adult, adolescent, and pediatric patients with and without a previous history of psychiatric disorder" 1.
Consider alternative therapies first: The FDA now recommends reserving montelukast "for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies" due to the neuropsychiatric risk profile 1.
Why This Matters for Quality of Life
The 2022 VigiBase analysis revealed that many cases described "a severe impact of the nightmares" on patients' daily lives 4. A 2025 pediatric cohort study of 1,163 children found that caregiver reports of neuropsychiatric symptoms increased from 14.8% to 34.3% after just 1 month of treatment 5. These data underscore that when these symptoms occur, they significantly impair quality of life and warrant immediate medication cessation.
The general principle from sleep medicine guidelines is that drugs affecting neurotransmitters (norepinephrine, serotonin, dopamine) can produce nightmares, and "it is not known if there is any long-term impact on nightmares after removal of the offending drug" 6—emphasizing the importance of prompt discontinuation when symptoms emerge.